Trials / Unknown
UnknownNCT04126460
High-risk Recurrent or Second Primary HNSCC With PD-1 Antibody Adjuvant After Salvage Surgery(RePASS)
High-risk Recurrent or Second Primary HNSCC With PD-1 Antibody Adjuvant After Salvage Surgery: The RePASS Study
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 41 (estimated)
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a non-randomized, phase II, open-label study. The goal of this clinical research study is to investigate the efficacy and safety of adjuvant Toripalimab in high-risk recurrent/secondary HNSCC after salvage surgery.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Toripalimab | Toripalimab is a type of PD-1 antibody |
Timeline
- Start date
- 2019-07-10
- Primary completion
- 2021-09-30
- Completion
- 2021-12-31
- First posted
- 2019-10-15
- Last updated
- 2019-10-15
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04126460. Inclusion in this directory is not an endorsement.